康恩贝：清喉咽含片获药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration certificate of the throat lozenge, which is expected to positively impact its performance [1] Group 1: Product Approval - The throat lozenge is classified as a Type 2 modified new drug in traditional Chinese medicine, aimed at nourishing yin, clearing the throat, and detoxifying [1] - It is indicated for the treatment of acute pharyngitis, specifically for symptoms associated with lung heat and yin deficiency [1] Group 2: Financial Impact - The company has incurred research and development expenses totaling 43.56 million yuan for the throat lozenge [1] - According to data from Minet, the market sales for throat medications in China are projected to reach approximately 7.664 billion yuan in 2024, reflecting a year-on-year growth of 7.41% [1] - The approval and subsequent production and sales of the throat lozenge are expected to have a positive effect on the company's financial performance [1]